Arcadia Biosciences approves reverse split plan affecting RKDA stock

Published on 10/05/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq requires USD 2.5 million in equity by October 15, 2026, versus USD 633,000. For RKDA stock, equity was USD 633,000 on June 30, 2026.

RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences (US0390143032) approved a reverse stock split ratio from 1-for-2 to 1-for-10 on September 10, 2026, while Nasdaq's equity deadline remains October 15, 2026. StockTitan reported the shareholder vote and the listing notice in its RKDA filing summary.

Reverse split authority approved

Shareholders representing 52.3 percent of outstanding common shares participated in the annual meeting, according to TipRanks on September 15, 2026. The vote also approved potential share issuance tied to Series A-1 Preferred Investment Options and a new 2026 Omnibus Equity Incentive Plan.

The reverse split authorization gives the board discretion to act before June 30, 2027, with a ratio ranging from 1-for-2 to 1-for-10. That measure is separate from an immediate split and gives management another tool as the company addresses Nasdaq's bid-price and equity standards.

Equity gap sets October deadline

Arcadia reported stockholders' equity of USD 633,000 as of June 30, 2026, against Nasdaq's USD 2.5 million minimum for continued listing. StockTitan says the company received the Nasdaq notice on August 31, 2026 and has until October 15, 2026 to submit a compliance plan.

The second-quarter 2026 report shows the pressure behind that deadline: revenue was USD 1.4 million and net loss attributable to common stockholders was USD 6.3 million. Cash and cash equivalents reached USD 4.2 million at June 30, 2026, while operating cash use was USD 319,000 for the quarter, according to the same filing summary.

Results date and Nasdaq quote

Investing.com lists November 5, 2026 as Arcadia's next results date and identifies the company as Nasdaq-listed under RKDA, with ISIN US0390143032. The company's investor page highlights second-quarter 2026 results and describes its work in agricultural innovation and plant-based wellness products.

On Nasdaq, RKDA was trading at USD 0.28 on October 5, 2026 at 3:29 p.m. ET. Its 52-week range was USD 0.22 to USD 6.71, and its market capitalization was USD 428.6 thousand at that quote.